Warnings, Columns-Drugs & Supplements, January 2006

January 20, 2006

Elidel and Protopic Labels Updated to Include Possible Cancer Risk WASHINGTON, D.C. - The Food and Drug Administration recently approved updated labels for eczema drugs Elidel and Protopic to include 'black box' warnings risk of cancer associated with the topical ointments. The FDA said on Jan. 19 that the boxed warning and medication guide will be distributed with Novartis Corp.'s Elidel Cream (pimecrolimus) and Astellas' Protopic Ointment (tacrolimus) to help ensure that patients are aware of the cancer risk. The new labels also clarify that these drugs are recommended for use as second-line treatments, the … Subscribe Now Purchase Article for $40.00 Registered User Log In Email Address Password Login Forgot your username or password? UPCOMING CONFERENCES HarrisMartin's MDL Conference September 25, 2024 - Nashville, TN Hutton Hotel MORE DETAILS HarrisMartin's Midwest Asbestos Litigation Conference September 27, 2024 - St. Louis, MO Four Seasons Hotel, St. Louis MORE DETAILS Sign Up For Email Alerts × Email address Publications Asbestos Benzene & Emerging Toxic Torts Litigation Camp Lejeune & Water Contamination Drugs & Medical Devices MDL Mass Tort & Class Action Monitor Reinsurance & Arbitration Talcum Powder Litigation Report Close Submit